Research

Hormonal

Tirzepatide (0.144 mg/kg) significantly reduces voluntary alcohol consumption, prevents binge-like drinking, and suppresses relapse-like behaviors in rodents.

Tirzepatide, a dual GLP-1/GIP agonist, significantly reduces alcohol consumption and prevents relapse in rodent models by attenuating dopamine reward signaling. While preclinical, these findings suggest potential for treating Alcohol Use Disorder (AUD) and its metabolic complications.

GoodSupportsHIGH confidence
Tirzepatide dose-dependently reduced voluntary alcohol consumption, prevented binge and relapse-like drinking, and maintained efficacy during repeated administration.
Christian E. Edvardsson et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2025

Why this rating

Strong preclinical evidence across multiple models and sexes, but not yet human clinical trials.

Source

Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents

Christian E. Edvardsson et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2025

DOI 10.1101/2025.08.26.672374

preprintCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →